The anticancer functions of RIG-I–like receptors, RIG-I and MDA5, and their applications in cancer therapy

Translational Research

Volumn 190, Issue , 2017, Pages 51-60

  Wu, Yuanbing ^a   Wu, Xinqiang ^a   Wu, Longhuo ^a   Wang, Xiangcai ^a   Liu, Zhiping ^a,b  

^a GANNAN MEDICAL UNIVERSITY   (China)

^b Ganzhou Cancer Precision Medicine Engineering Research Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HELICASE; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; RETINOIC ACID INDUCIBLE PROTEIN I; RIG I LIKE RECEPTOR; UNCLASSIFIED DRUG; DDX58 PROTEIN, HUMAN; IFIH1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CARCINOGENESIS; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; MALIGNANT NEOPLASM; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; DEAD BOX PROTEIN 58; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-INDUCED HELICASE, IFIH1; NEOPLASMS;

EID: 85029713403     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2017.08.004     Document Type: Review

References (68)

1. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. Chen, W., Zheng, R., Baade, P.D., et al. Cancer statistics in China, 2015. CA Cancer J Clin 66 (2016), 115–132.
3. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
4. Elinav, E., Nowarski, R., Thaiss, C.A., Hu, B., Jin, C., Flavell, R.A., Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13 (2013), 759–771.
5. Grivennikov, S.I., Greten, F.R., Karin, M., Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
6. Koebel, C.M., William, V., Swann, J.B., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 (2008), 903–907.
7. Kroemer, G., Galluzzi, L., Kepp, O., Zitvogel, L., Immunogenic cell death in cancer therapy. Annu Rev Immunol 31 (2013), 51–72.
8. Sideras, K., Braat, H., Kwekkeboom, J., et al. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Mol Pharmacol 40 (2014), 513–522.
9. Zheng, L., Xue, J., Jaffee, E.M., Habtezion, A., Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology 144 (2013), 1230–1240.
10. Khanna, P., Blais, N., Gaudreau, P.O., Corrales-Rodriguez, L., Immunotherapy Comes of Age in lung cancer. Clin Lung Cancer 18 (2017), 13–22.
11. Boon, T., Coulie, P.G., Eynde, B.J., Bruggen, P.V., Human T cell responses against melanoma. Annu Rev Immunol 24 (2006), 175–208.
12. Roulois, D., Loo Yau, H., Singhania, R., et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162 (2015), 961–973.
13. Chiappinelli, K.B., Strissel, P.L., Desrichard, A., et al. Inhibiting DNA Methylation causes an interferon response in cancer via dsRNA including endogenous Retroviruses. Cell 162 (2015), 974–986.
14. Besch, R., Poeck, H., Hohenauer, T., et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 119 (2009), 2399–2411.
15. Onoguchi, K., Yoneyama, M., Fujita, T., Retinoic acid-inducible gene-I-like receptors. J Interferon Cytokine Res 31 (2011), 27–31.
16. Loo, Y.-M., Gale, M., Immune signaling by RIG-I-like receptors. Immunity 34 (2011), 680–692.
17. Gurtler, C., Bowie, A.G., Innate immune detection of microbial nucleic acids. Trends Microbiol 21 (2013), 413–420.
18. Kato, H., Takahasi, K., Fujita, T., RIG-I-like receptors: cytoplasmic sensors for non-self RNA. Immunol Rev 243 (2011), 91–98.
19. Bruns, A.M., Horvath, C.M., LGP2 synergy with MDA5 in RLR-mediated RNA recognition and antiviral signaling. Cytokine 74 (2015), 198–206.
20. Au-Yeung, N., Mandhana, R., Horvath, C.M., Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway. JAKSTAT, 2, 2013, e23931.
21. Poeck, H., Besch, R., Maihoefer, C., et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 14 (2008), 1256–1263.
22. Meng, G., Xia, M., Xu, C., Yuan, D., Schnurr, M., Wei, J., Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation. Int J Cancer 134 (2014), 1958–1971.
23. He, L., Chen, Y., Wu, Y., Xu, Y., Zhang, Z., Liu, Z., Nucleic acid sensing pattern recognition receptors in the development of colorectal cancer and colitis. Cell Mol Life Sci 74 (2017), 2395–2411.
24. Schnurr, M., Duewell, P., Induction of immunogenic cell death by targeting RIG-I-like helicases in pancreatic cancer. Oncoimmunology, 3, 2014, e955687.
25. Yoneyama, M., Kikuchi, M., Natsukawa, T., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5 (2004), 730–737.
26. Hornung, V., Ellegast, J., Kim, S., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 314 (2006), 994–997.
27. Goubau, D., Schlee, M., Deddouche, S., et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates. Nature 514 (2014), 372–375.
28. Matsushima-Miyagi, T., Hatano, K., Nomura, M., et al. TRAIL and Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 18 (2012), 6271–6283.
29. Hu, J., He, Y., Yan, M., et al. Dose dependent activation of retinoic acid-inducible gene-I promotes both proliferation and apoptosis signals in human head and neck squamous cell carcinoma. PLoS One, 8, 2013, e58273.
30. Glas, M., Coch, C., Trageser, D., et al. Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma. Stem Cells 31 (2013), 1064–1074.
31. Qu, J., Hou, Z., Han, Q., Zhang, C., Tian, Z., Zhang, J., Poly(I: C) exhibits an anti-cancer effect in human gastric adenocarcinoma cells which is dependent on RLRs. Int Immunopharmacol 17 (2013), 814–820.
32. Kumar, S., Ingle, H., Mishra, S., et al. IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity. Cell Death Dis, 6, 2015, e1758.
33. Palchetti, S., Starace, D., De Cesaris, P., Filippini, A., Ziparo, E., Riccioli, A., Transfected poly(I: C) activates different dsRNA receptors, leading to apoptosis or immunoadjuvant response in androgen-independent prostate cancer cells. J Biol Chem 290 (2015), 5470–5483.
34. Duewell, P., Steger, A., Lohr, H., et al. RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells. Cell Death Differ 21 (2014), 1825–1837.
35. Ellermeier, J., Wei, J., Duewell, P., et al. Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer. Cancer Res 73 (2013), 1709–1720.
36. Kübler, K., Gehrke, N., Riemann, S., et al. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res 70 (2010), 5293–5304.
37. Zhu, H., Xu, W.Y., Hu, Z., et al. RNA virus receptor Rig-I monitors gut microbiota and inhibits colitis-associated colorectal cancer. J Exp Clin Cancer Res, 36, 2017, 2.
38. Hou, J., Zhou, Y., Zheng, Y., et al. Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma. Cancer Cell 25 (2014), 49–63.
39. Chattopadhyay, S., Fensterl, V., Zhang, Y., Veleeparambil, M., Yamashita, M., Sen, G.C., Role of interferon regulatory factor 3-mediated apoptosis in the establishment and maintenance of persistent infection by Sendai virus. J Virol 87 (2013), 16–24.
40. Chattopadhyay, S., Sen, G.C., RIG-I-like receptor-induced IRF3 mediated pathway of apoptosis (RIPA): a new antiviral pathway. Protein Cell 8 (2017), 165–168.
41. Hayakari, R., Matsumiya, T., Xing, F., Yoshida, H., Hayakari, M., Imaizumi, T., Critical role of IRF-3 in the direct regulation of dsRNA-induced retinoic acid-inducible Gene-I (RIG-I) expression. PLoS One, 11, 2016, e0163520.
42. Knowlton, J.J., Dermody, T.S., Holm, G.H., Apoptosis induced by mammalian reovirus is beta interferon (IFN) independent and enhanced by IFN regulatory factor 3- and NF-kappaB-dependent expression of Noxa. J Virol 86 (2012), 1650–1660.
43. Peltier, D.C., Lazear, H.M., Farmer, J.R., Diamond, M.S., Miller, D.J., Neurotropic arboviruses induce interferon regulatory factor 3-mediated neuronal responses that are cytoprotective, interferon independent, and inhibited by Western equine encephalitis virus capsid. J Virol 87 (2012), 1821–1833.
44. Arthur, J.C., Perezchanona, E., Mühlbauer, M., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338 (2012), 120–123.
45. Kado, S., Uchida, K., Funabashi, H., et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res 61 (2001), 2395–2398.
46. Liu, Z., Dou, C., Jia, Y., et al. RIG-I suppresses the migration and invasion of hepatocellular carcinoma cells by regulating MMP9. Int J Oncol 46 (2015), 1710–1720.
47. Egeblad, M., Werb, Z., New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002), 161–174.
48. van den Boorn Jasper, G., Hartmann, G., Turning tumors into vaccines: Co-opting the innate immune system. Immunity 39 (2013), 27–37.
49. Schnurr, M., Duewell, P., Breaking tumor-induced immunosuppression with 5'-triphosphate siRNA silencing TGFbeta and activating RIG-I. Oncoimmunology, 2, 2013, e24170.
50. Wolf, D., Heine, A., Brossart, P., Implementing combinatorial immunotherapeutic regimens against cancer: the concept of immunological conditioning. Oncoimmunology, 3, 2014, e27588.
51. Yasufumi, K., The RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis. Oncoimmunology, 2, 2013, e23566.
52. Ranoa, D.R., Parekh, A.D., Pitroda, S.P., et al. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget 7 (2016), 26496–26515.
53. Saito, T., Hirai, R., Loo, Y.M., et al. Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A 104 (2007), 582–587.
54. Zitvogel, L., Kroemer, G., Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest 119 (2009), 2127–2130.
55. Kang, D.C., Gopalkrishnan, R.V., Lin, L., et al. Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene. Oncogene 23 (2004), 1789–1800.
56. Lin, L., Su, Z., Lebedeva, I.V., et al. Activation of Ras/Raf protects cells from melanoma differentiation-associated gene-5-induced apoptosis. Cell Death Differ 13 (2006), 1982–1993.
57. Hsu, W.M., Huang, C.C., Lee, H.Y., et al. MDA5 complements TLR3 in suppression of neuroblastoma. Oncotarget 6 (2015), 24935–24946.
58. Inao, T., Harashima, N., Monma, H., et al. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I: C), on human breast cancer. Breast Cancer Res Treat 134 (2012), 89–100.
59. Duewell, P., Beller, E., Kirchleitner, S.V., et al. Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma. Oncoimmunology, 4, 2015, e1029698.
60. Peng, S., Geng, J., Sun, R., Tian, Z., Wei, H., Polyinosinic-polycytidylic acid liposome induces human hepatoma cells apoptosis which correlates to the up-regulation of RIG-I like receptors. Cancer Sci 100 (2009), 529–536.
61. Shi, M., Chen, X., Ye, K., Yao, Y., Li, Y., Application potential of toll-like receptors in cancer immunotherapy: Systematic review. Medicine, 95, 2016, e3951.
62. Sistigu, A., Yamazaki, T., Vacchelli, E., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20 (2014), 1301–1309.
63. Yu, X., Wang, H., Li, X., et al. Activation of the mda-5-IPS-1 viral sensing pathway induces cancer cell death and type I IFN-dependent antitumor immunity. Cancer Res 76 (2016), 2166–2176.
64. Yu, C.Y., Chiang, R.L., Chang, T.H., Liao, C.L., Lin, Y.L., The interferon stimulator mitochondrial antiviral signaling protein facilitates cell death by disrupting the mitochondrial membrane potential and by activating caspases. J Virol 84 (2010), 2421–2431.
65. El Maadidi, S., Faletti, L., Berg, B., et al. A novel mitochondrial MAVS/Caspase-8 platform links RNA virus-induced innate antiviral signaling to Bax/Bak-independent apoptosis. J Immunol 192 (2014), 1171–1183.
66. Chattopadhyay, S., Kuzmanovic, T., Zhang, Y., Wetzel, J.L., Sen, G.C., Ubiquitination of the transcription factor IRF-3 activates RIPA, the apoptotic pathway that protects mice from viral Pathogenesis. Immunity 44 (2016), 1151–1161.
67. Akasaka, T., Tsujii, M., Kondo, J., et al. 5-FU resistance abrogates the amplified cytotoxic effects induced by inhibiting checkpoint kinase 1 in p53mutated colon cancer cells. Int J Oncol 46 (2015), 63–70.
68. Mowa, M.B., Crowther, C., Arbuthnot, P., Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Expert Opin Drug Deliv 7 (2010), 1373–1385.